# Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

> **NCT05242159** · — · UNKNOWN · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 300 (estimated)

## Conditions studied

- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05242159
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-15
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242159, "Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05242159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*